Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$0.52
EPS est.
$0.42
EPS surprise
+24.40%
1-day move
-0.72%
Concentra Group Holdings reported a better-than-expected EPS of $0.52, exceeding estimates by 24.40%. However, the stock reacted negatively, declining by 0.72%. The lack of revenue data and management commentary may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.52 | N/A | +24.40% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Concentra Group Holdings Parent, Inc. operates in the health care sector, focusing on health care facilities. As a company with a market cap of $4 billion, it plays a significant role in providing health services, which are increasingly important in today's health-conscious environment.
Last quarter
In Q1-2026, Concentra reported an EPS of $0.39, beating estimates by 11.43%. The stock reacted positively, gaining 3.42% the following day.
EPS beat streak
4Q
EPS beat rate
88%
Avg EPS surprise
+8.34%
Avg 1-day reaction
+0.03%
Overall expectations for Concentra's upcoming earnings are mixed, with no analyst estimates available. Investors will be looking for signs of continued profitability and growth.
Bull case
If Concentra can maintain or exceed its previous EPS growth trend, it could signal strong operational performance and investor confidence.
Bear case
Conversely, if the company shows signs of stagnation or declining revenue, it could lead to negative sentiment and a drop in stock price.
The print will turn on these.
Q1
What will be the reported EPS for Q2-2026?
EPS is a critical measure of profitability, and any significant deviation from previous trends could influence investor sentiment.
Q2
How is revenue growth trending compared to previous quarters?
Understanding revenue growth will provide insights into the company's operational health and market demand for its services.
—
Est. EPS
$0.59
Est. Rev
$1.3B
Impl. Move
±25.5%
Why consensus could be wrong
The Street may underestimate Concentra's ability to capitalize on growing demand for health care services, especially in light of recent trends.
Supporting evidence
Concentra has consistently beaten EPS estimates in the past, indicating strong management performance.
The options market is pricing a larger move than historical averages, suggesting that investors expect significant news.
Recent trends in health care spending could favor Concentra's growth potential.
Key risk
If EPS comes in below $0.35, it could undermine confidence in the company's growth narrative.
Pre-commit to what would confirm each case.
This quarter's performance will hinge on whether Concentra can maintain its growth trajectory in a competitive health care environment.
Bull confirmed if
An EPS of $0.40 or higher would confirm the bull case, indicating strong profitability.
Bear confirmed if
An EPS below $0.35 would confirm the bear case, suggesting potential operational issues.
What the market is pricing for the move.
Implied Move
±10.87%
Historical Avg
±1.6%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±10.9% while CON has averaged ±1.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
24.7%
Smart-money positioning from the most recent 13F filings.
Institutional
90.62%
of float
Insider
9.65%
of float
Holders
405
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
17,753,714 sh · $646.2M
13.92%
4.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Concentra beats expectations, history suggests the stock could rise by about 1.87%, confirming strong operational performance.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
If the company misses expectations, history suggests a potential decline of around 1.30%, indicating investor disappointment.
The lines on the call that would change the story.
Price (T.Rowe) Associates Inc
17,715,257 sh · $644.8M
13.89%
4.0%
Vanguard Portfolio Management LLC
6,817,456 sh · $248.2M
5.35%
1.2%
Vanguard Capital Management LLC
5,129,815 sh · $186.7M
4.02%
0.7%
State Street Corporation
4,840,099 sh · $176.2M
3.80%
5.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.